docwirenews.com
Darvadstrocel Fails Primary Endpoint in Crohn's Disease Trial | Docwire News
This trial shows darvadstrocel did not outperform placebo for complex perianal Crohn’s fistulas, so it does not support changing care now. High healing rates after surgical curettage and closure suggest the surgical step itself may be a key driver of fistula healing.
The findings matter for patients considering investigational cell therapies for perianal disease.
Patients with complex perianal Crohn’s disease, clinicians managing perianal fistulas, researchers in cell therapy and surgical treatment of fistulas.
What To Know
Darvadstrocel (a stem-cell dispersion) did not meet the primary endpoint of combined remission at week 24 versus placebo in the phase 3 ADMIRE CD II trial for complex perianal Crohn’s fistulas. Both groups received vigorous surgical curettage and internal opening closure, and placebo response rates were high, which the article highlights as a likely factor.
This was a randomized, double-blind, placebo-controlled phase 3 trial enrolling 568 adults with complex perianal Crohn’s fistulas. At week 24, combined remission occurred in 48.8% of darvadstrocel patients and 46.3% of placebo patients (no significant difference). Safety profiles were similar through 52 weeks with no new safety signals reported.
The report notes that the surgical preparation (vigorous curettage and closure) given to all participants may have driven unexpectedly high placebo responses, suggesting surgical conditioning could be an important contributor to fistula healing.
The article also suggests future research might explore different cell types (eg, regulatory T cells) or stem cell components (eg, extracellular vesicles).
This article summarizes trial results and does not imply changes to current clinical practice; patients should discuss treatment options with their providers and not change therapy based on this report alone.
ADMIRE CD II was a large, phase 3 randomized trial; lack of benefit may reflect a true absence of added effect from darvadstrocel or an unexpectedly strong effect of the standardized surgical conditioning given to all participants. The article recommends further research into other cell types or components and does not report new safety concerns.
The source summarizes peer-reviewed trial results; readers should consult the original publication or their clinician for clinical decisions.
